92 related articles for article (PubMed ID: 26632190)
1. Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8.
Senda A; Mukai Y; Toda T; Hayakawa T; Yamashita M; Eliasson E; Rane A; Inotsume N
Biol Pharm Bull; 2015; 38(12):1975-9. PubMed ID: 26632190
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.
Senda A; Mukai Y; Hayakawa T; Kato Y; Eliasson E; Rane A; Toda T; Inotsume N
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):239-245. PubMed ID: 28374982
[TBL] [Abstract][Full Text] [Related]
3. The Inhibitory Effect of Telmisartan on the Metabolism of Arachidonic Acid by CYP2C9 and CYP2C8: An in Vitro Study.
Kato Y; Mukai Y; Rane A; Inotsume N; Toda T
Biol Pharm Bull; 2017; 40(9):1409-1415. PubMed ID: 28867723
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin II receptor blockers on serum levels of epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids in patients admitted to a cardiovascular center.
Kato Y; Senda A; Mukai Y; Yamashita M; Sasaoka Y; Hanada M; Hongo F; Hirokami M; Rane A; Inotsume N; Toda T
Eur J Clin Pharmacol; 2021 Jun; 77(6):887-894. PubMed ID: 33409683
[TBL] [Abstract][Full Text] [Related]
5. Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer.
Wei X; Zhang D; Dou X; Niu N; Huang W; Bai J; Zhang G
BMC Cancer; 2014 Nov; 14():841. PubMed ID: 25406731
[TBL] [Abstract][Full Text] [Related]
6. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
Marshall TG; Lee RE; Marshall FE
Theor Biol Med Model; 2006 Jan; 3():1. PubMed ID: 16403216
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of telmisartan and fluvastatin on arachidonic acid metabolism in human liver microsomes.
Kato Y; Mukai Y; Rane A; Inotsume N; Toda T
Xenobiotica; 2018 Sep; 48(9):898-903. PubMed ID: 28933256
[TBL] [Abstract][Full Text] [Related]
8. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
Zaiken K; Hudd TR; Cheng JW
Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
[TBL] [Abstract][Full Text] [Related]
9. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders.
Shahabi P; Siest G; Meyer UA; Visvikis-Siest S
Pharmacol Ther; 2014 Nov; 144(2):134-61. PubMed ID: 24882266
[TBL] [Abstract][Full Text] [Related]
10. Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from VigiBase(®).
Viola E; Coggiola Pittoni A; Drahos A; Moretti U; Conforti A
Drug Saf; 2015 Oct; 38(10):889-94. PubMed ID: 26187686
[TBL] [Abstract][Full Text] [Related]
11. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Cabaleiro T; Román M; Ochoa D; Talegón M; Prieto-Pérez R; Wojnicz A; López-Rodríguez R; Novalbos J; Abad-Santos F
Drug Metab Dispos; 2013 Jan; 41(1):224-9. PubMed ID: 23118328
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous Determination Method of Epoxyeicosatrienoic Acids and Dihydroxyeicosatrienoic Acids by LC-MS/MS System.
Mukai Y; Toda T; Takeuchi S; Senda A; Yamashita M; Eliasson E; Rane A; Inotsume N
Biol Pharm Bull; 2015; 38(10):1673-9. PubMed ID: 26424030
[TBL] [Abstract][Full Text] [Related]
14. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases.
Zordoky BN; El-Kadi AO
Pharmacol Ther; 2010 Mar; 125(3):446-63. PubMed ID: 20093140
[TBL] [Abstract][Full Text] [Related]
16. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs.
Nithipatikom K; DiCamelli RF; Kohler S; Gumina RJ; Falck JR; Campbell WB; Gross GJ
Anal Biochem; 2001 May; 292(1):115-24. PubMed ID: 11319825
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
19. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450.
Yang R; Luo Z; Liu Y; Sun M; Zheng L; Chen Y; Li Y; Wang H; Chen L; Wu M; Zhao H
Curr Drug Metab; 2016; 17(7):681-91. PubMed ID: 27216792
[TBL] [Abstract][Full Text] [Related]
20. Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid.
Nithipatikom K; Grall AJ; Holmes BB; Harder DR; Falck JR; Campbell WB
Anal Biochem; 2001 Nov; 298(2):327-36. PubMed ID: 11700990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
